OncoMatch

OncoMatch/Clinical Trials/NCT05668858

A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Is NCT05668858 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including SI-B001 and SI-B003 for squamous cell carcinoma of head and neck.

Phase 1/2RecruitingSichuan Baili Pharmaceutical Co., Ltd.NCT05668858Data as of May 2026

Treatment: SI-B001 · SI-B003Phase Ib: To observe the safety and tolerability of SI-B001+SI-B003 in combination and to identify RP2D in locally advanced or metastatic head and neck squamous cell carcinoma indications. Initial efficacy, pharmacokinetic characteristics and immunogenicity were evaluated. Phase II: To evaluate the efficacy of SI-B001+SI-B003 two-drug combination chemotherapy. Safety and tolerance, PK/PD, immunogenicity were evaluated.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: systemic chemotherapy

Exception: chemotherapy administered as part of multimodal treatment for locally advanced disease

those who have received systemic chemotherapy, excluding chemotherapy administered as part of multimodal treatment for locally advanced disease

Cannot have received: chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy, or other antitumor treatments

Receipt of chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first dose of the study drug

Lab requirements

Blood counts

Kidney function

Liver function

Cardiac function

No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%

Organ function levels must meet the requirements; No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%; Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × ULN; Urine protein ≤1+ or ≤1000 mg/24h

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify